Recently, according to the Xin’an Evening News, 57-year-old Aunt Su (pseudonym) from Bengbu, Anhui underwent bilateral ovary and hysterectomy seven years ago because of ovarian mass. Shows diffuse large B-cell lymphoma. In the few years after the diagnosis, Aunt Su went to many hospitals for treatment, but the results were not satisfactory, and her condition kept recurring.
In February this year, Aunt Su was hospitalized again for treatment. When she was admitted to the hospital, Aunt Su had obvious swelling and pain in her face, and there was an obvious mass on the left side of her face. She had difficulty breathing and could not lie down and rest normally. . Considering that Auntie Su had performed a number of comprehensive treatments, the results were not satisfactory, and the expert team decided to perform CAR-T cell therapy for Auntie Su.
Only 10 days after the injection, Aunt Su’s facial mass gradually disappeared, and a PET-CT re-examination one month later showed complete remission of the disease (CR, all target lesions disappeared, no new lesions appeared, and tumor markers appeared things are normal for at least 4 weeks), and Aunt Su’s life gradually returned to normal.
In September 2021, the news about 1.2 million high-priced anti-tumor drugs per injection was overwhelming. Most people were surprised by its sky-high price, and many people questioned its effectiveness, and of course some Late-stage lung cancer patients feel that they have grabbed a life-saving straw and come to consult whether it can be used for lung cancer. Since June 2021, the CAR-T product, Akilence injection, which sells for up to 1.2 million yuan, has been launched, and more than 100 patients have spent a lot of money on this drug.
